- GLP-1 receptor agonists like Ozempic and Wegovy, originally intended as diabetes medications, have gained popularity for weight loss, leading to global shortages despite having modest benefits
- Research shows these drugs reduce seizures and substance addiction risks, but they increase the likelihood of 19 other health conditions, including fainting, kidney problems and pancreatic issues
- Common side effects include nausea, diarrhea, vomiting and abdominal pain, with potential risks of acute pancreatitis and thyroid cancer, making the trade-off dangerous for users
- Ozempic’s manufacturer Novo Nordisk reported $40.6 billion in revenue, highlighting how the “magic pill” mentality and ultraprocessed food consumption create a profitable cycle for pharmaceutical companies and food manufacturers
- Instead of relying on weight loss drugs, focus on optimizing cellular energy production through dietary changes, avoiding vegetable oils and supporting your gut and mitochondrial health
Read the full article here.
